Zobrazeno 1 - 10
of 142
pro vyhledávání: '"Bent K Jakobsen"'
Autor:
Yuqi Zhou, Julie Jadlowsky, Caitlin Baiduc, Alex W Klattenhoff, Zhilin Chen, Alan D Bennett, Nicholas J Pumphrey, Bent K Jakobsen, James L Riley
Publikováno v:
PLoS Pathogens, Vol 19, Iss 12, p e1011853 (2023)
Engineered T cells hold great promise to become part of an effective HIV cure strategy, but it is currently unclear how best to redirect T cells to target HIV. To gain insight, we generated engineered T cells using lentiviral vectors encoding one of
Externí odkaz:
https://doaj.org/article/8eb7c6b495114717be1c16a3559d1cd9
Autor:
Andrew B Gerry, Bent K Jakobsen, David Krige, Rahul C Khanolkar, James A Davies, Alexander T Baker, Thomas A Webb, Alicia Teijeira-Crespo, Hanni K Uusi-Kerttula, Lucy M Williams, Samantha L Moore, Johanne M Pentier, Alan L Parker, David K Cole
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/9e3c849f17ae4098a4e02487851dbaa0
Autor:
Jane Harper, Katherine J Adams, Giovanna Bossi, Debbie E Wright, Andrea R Stacey, Nicole Bedke, Ruth Martinez-Hague, Dan Blat, Laure Humbert, Hazel Buchanan, Gabrielle S Le Provost, Zoe Donnellan, Ricardo J Carreira, Samantha J Paston, Luise U Weigand, Martina Canestraro, Joseph P Sanderson, Sophie Botta Gordon-Smith, Kate L Lowe, Karolina A Rygiel, Alex S Powlesland, Annelise Vuidepot, Namir J Hassan, Brian J Cameron, Bent K Jakobsen, Joseph Dukes
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205491 (2018)
Robust preclinical testing is essential to predict clinical safety and efficacy and provide data to determine safe dose for first-in-man studies. There are a growing number of examples where the preclinical development of drugs failed to adequately p
Externí odkaz:
https://doaj.org/article/c3d7165394b5442098ed39f7073a5fbd
Autor:
Gunnar Hedlund, Helena Eriksson, Anette Sundstedt, Göran Forsberg, Bent K Jakobsen, Nicholas Pumphrey, Karin Rödström, Karin Lindkvist-Petersson, Per Björk
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e79082 (2013)
The T lymphocytes are the most important effector cells in immunotherapy of cancer. The conceptual objective for developing the tumor targeted superantigen (TTS) ABR-217620 (naptumomab estafenatox, 5T4Fab-SEA/E-120), now in phase 3 studies for advanc
Externí odkaz:
https://doaj.org/article/7714f2df1eeb429698d214d001f27ccb
Autor:
Gediminas Matulis, Joseph P Sanderson, Nikolai M Lissin, Maria B Asparuhova, Gopal R Bommineni, Daniel Schümperli, Richard R Schmidt, Peter M Villiger, Bent K Jakobsen, Stephan D Gadola
Publikováno v:
PLoS Biology, Vol 8, Iss 6, p e1000402 (2010)
Invariant Natural Killer T cells (iNKT) are a versatile lymphocyte subset with important roles in both host defense and immunological tolerance. They express a highly conserved TCR which mediates recognition of the non-polymorphic, lipid-binding mole
Externí odkaz:
https://doaj.org/article/228093b8dfbf408ab4d907a528db008d
Autor:
Alan D. Bennett, Barbara Tavano, Sara Brett, Manoj Saini, Adriano Quattrini, David J. Figueroa, Katherine L Crossland, Terri V Cornforth, Cedrik M. Britten, Joanna E. Brewer, Caitriona O'Connor, Jonathan D. Silk, Dylan Steiner, Alistair G Rust, Andrew B. Gerry, Ryan Wong, Katherine Adams, Joseph P. Sanderson, Annette Pachnio, Carlos E Peredo, Preetha Viswanathan, Junping Jing, Rachel J. M. Abbott, Guy E. Wiedermann, Laura L. Quinn, Lea Patasic, Bent K. Jakobsen
Publikováno v:
The Journal of Immunology. 208:169-180
Adoptive T cell therapy with T cells expressing affinity-enhanced TCRs has shown promising results in phase 1/2 clinical trials for solid and hematological tumors. However, depth and durability of responses to adoptive T cell therapy can suffer from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c2e78d7f1803cc7f793de4dea9cfdab
https://doi.org/10.4049/jimmunol.2001357
https://doi.org/10.4049/jimmunol.2001357
Autor:
R. Martinez Hague, Fiona Chester, Jane Harper, S. Griffin, Angharad Lloyd, Emma Baston, R. Mulvaney, Annelise Vuidepot, K. Smith, S. Harper, K. Wiederhold, A.R. Stacey, Andrew Alexander Knox, S. Malla, K.L. Lowe, C.H. Coles, Z. Donnellan, Samantha Paston, Joseph Dukes, Bent K. Jakobsen, R.A. Robinson, M. Aleksic, A. Walker, Michelle L. McCully
Publikováno v:
The Journal of Immunology. 204:1943-1953
The molecular rules driving TCR cross-reactivity are poorly understood and, consequently, it is unclear the extent to which TCRs targeting the same Ag recognize the same off-target peptides. We determined TCR–peptide–HLA crystal structures and, u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b03e627be240f30ea60a4a4dabb09d
https://doi.org/10.4049/jimmunol.1900915
https://doi.org/10.4049/jimmunol.1900915
Publikováno v:
Marine Simulation and Ship Manoeuvrability ISBN: 9780203748077
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edd6cda9ca4970efc92b4599057fd5c7
https://doi.org/10.1201/9780203748077-7
https://doi.org/10.1201/9780203748077-7
Publikováno v:
Cancer Treatment Reviews. 77:35-43
Immunotherapeutic strategies have revolutionised cancer therapy in recent years, bringing meaningful improvements in outcomes for patients with previously intractable conditions. These successes have, however, been largely limited to certain types of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7484f3f3317e0787c6d1fc7205b08ac0
https://doi.org/10.1016/j.ctrv.2019.06.001
https://doi.org/10.1016/j.ctrv.2019.06.001
Autor:
Malkit Sami, Ben de Wet, Elizabeth A. Potter, Rory M. Crean, Katy A. Lloyd, Velupillai Srikannathasan, Nikolai Lissin, Milos Aleksic, Anitha Jeyanthan, Miriam Hock, David K. Cole, Peter Eamon Molloy, Pierre J. Rizkallah, Marco Lepore, Annelise Vuidepot, Christopher J. Holland, Brian Cameron, Thomas Blicher, Robert J. Pengelly, Christopher R. Pudney, Ross A. Robinson, Johanne M. Pentier, Thomas E. Spinner, Marc W. van der Kamp, Bent K. Jakobsen, Nathaniel Liddy, Paul J. Conroy, Stephen Harper, Angharad Lloyd
Publikováno v:
J Clin Invest
Tumor-associated peptide-human leukocyte antigen complexes (pHLAs) represent the largest pool of cell surface-expressed cancer-specific epitopes, making them attractive targets for cancer therapies. Soluble bispecific molecules that incorporate an an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cbe9e3e9f83c5de1920113bed8d5316
https://europepmc.org/articles/PMC7190993/
https://europepmc.org/articles/PMC7190993/